Drug Type Small molecule drug |
Synonyms Larotaxel, PNU 100940, PNU-100940 + [8] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC45H57NO16 |
InChIKeySEFGUGYLLVNFIJ-QDRLFVHASA-N |
CAS Registry192573-38-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Larotaxel Dihydrate | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Bladder Carcinoma | Phase 3 | United Kingdom | 11 Dec 2007 | |
| Pancreatic Cancer | Phase 3 | United States | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Belgium | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Brazil | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Canada | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Chile | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Colombia | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Czechia | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Finland | 01 Dec 2006 | |
| Pancreatic Cancer | Phase 3 | Germany | 01 Dec 2006 |





